表紙
市場調查報告書

藥劑溶出性血管支架 (DES):醫療設備的開發平台評估 (2019年)

Drug Eluting Stents (DES) - Medical Devices Pipeline Assessment, 2019

出版商 GlobalData 商品編碼 328676
出版日期 內容資訊 英文 247 Pages
訂單完成後即時交付
價格
Back to Top
藥劑溶出性血管支架 (DES):醫療設備的開發平台評估 (2019年) Drug Eluting Stents (DES) - Medical Devices Pipeline Assessment, 2019
出版日期: 2019年12月20日內容資訊: 英文 247 Pages
簡介

本報告提供全球藥劑溶出性血管支架 (DES) 市場上,主要開發中產品 (醫療設備)與其臨床實驗的進展相關調查,產品特性比較分析 (臨床實驗的各進展階段) ,再加上主要企業簡介及代表性產品,近來的市場動靜 (資本交易、事業聯盟等) 的資訊彙整,為您概述為以下內容。

第1章 目錄

第2章 簡介

  • 藥劑溶出性血管支架 (DES)的概要

第3章 現在臨床實驗中的產品

  • 開發中產品:各臨床實驗階段
  • 開發中產品:各領域
  • 開發中產品:各法規途徑
  • 開發中產品:各估計認證時期
  • 現在進行中的臨床實驗

第4章 藥劑溶出性血管支架 (DES) :各企業現在臨床實驗中的開發中產品

  • 藥劑溶出性血管支架的企業:各臨床實驗階段的開發中產品
  • 藥劑溶出性血管支架:各臨床實驗階段的開發中產品

第5章 藥劑溶出性血管支架 (DES)的企業、產品概要

  • Aachen Resonance GmbH
    • 開發中產品及進行中的臨床實驗概要
  • Abbott Vascular Inc
  • Adcomp Technologies Inc.
  • Advanced Bifurcation Systems Inc
  • Aeon Bioscience
  • AlviMedica Medical Technologies Inc
  • B. Braun Melsungen AG
  • Biosensors International Group Ltd
  • Biotronik AG
  • Biotronik SE & Co KG
  • Boston Scientific
  • Cardionovum GmbH
  • Cardiorev Pte Ltd (Inactive)
  • Columbia University
  • Concept Medical Inc
  • Cordis Corp
  • DISA Vascular (Pty) Ltd
  • Elixir Medical Corp
  • Envision Scientific Pvt Ltd
  • I.B.S. S.p.A
  • InspireMD Inc
  • JW Medical Systems Ltd
  • KANEKA
  • Liaoning Biomedical Materials R&D Center Co Ltd
  • MangoGen Pharma Inc
  • Medinol Ltd
  • Medlogics Device Corp (Inactive)
  • Medtronic plc
  • MicroPort Scientific Corp
  • MIV Therapeutics Inc
  • NuVascular Technologies Inc
  • Relisys Medical Devices Ltd
  • REVA Medical Inc
  • Shanghai Bio-heart Biological Technology Co Ltd
  • Sino Medical Sciences Technology Inc
  • Stentys SA
  • Svelte Medical Systems Inc
  • Terumo Corporation
  • TissueGen Inc
  • University of Strathclyde
  • VasoTech Inc.

第6章 藥劑溶出性血管支架 (DES) 市場:目前的趨勢 (共77件)

第7章 附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDME0890EPD

GlobalData's Medical Devices sector report, "Drug Eluting Stents (DES) - Medical Devices Pipeline Assessment, 2019" provides an overview of Drug Eluting Stents (DES) currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Drug Eluting Stents (DES) pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

  • Extensive coverage of the Drug Eluting Stents (DES) under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Drug Eluting Stents (DES) and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment / industry

Reasons to buy

The report enables you to -

  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of Drug Eluting Stents (DES) under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product's current stage of development, territory and estimated launch date

Table of Contents

Table of Contents

  • 1.1 List of Tables
  • 1.2 List of Figures

2 Introduction

  • 2.1 Drug Eluting Stents (DES) Overview

3 Products under Development

  • 3.1 Drug Eluting Stents (DES) - Pipeline Products by Stage of Development
  • 3.2 Drug Eluting Stents (DES) - Pipeline Products by Territory
  • 3.3 Drug Eluting Stents (DES) - Pipeline Products by Regulatory Path
  • 3.4 Drug Eluting Stents (DES) - Pipeline Products by Estimated Approval Date
  • 3.5 Drug Eluting Stents (DES) - Ongoing Clinical Trials

4 Drug Eluting Stents (DES) - Pipeline Products under Development by Companies

  • 4.1 Drug Eluting Stents (DES) Companies - Pipeline Products by Stage of Development
  • 4.2 Drug Eluting Stents (DES) - Pipeline Products by Stage of Development

5 Drug Eluting Stents (DES) Companies and Product Overview

  • 5.1 Aachen Resonance GmbH Company Overview
    • 5.1.1 Aachen Resonance GmbH Pipeline Products & Ongoing Clinical Trials Overview
  • 5.2 Abbott Vascular Inc Company Overview
    • 5.2.1 Abbott Vascular Inc Pipeline Products & Ongoing Clinical Trials Overview
  • 5.3 Adcomp Technologies Inc. Company Overview
    • 5.3.1 Adcomp Technologies Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.4 Advanced Bifurcation Systems Inc Company Overview
    • 5.4.1 Advanced Bifurcation Systems Inc Pipeline Products & Ongoing Clinical Trials Overview
  • 5.5 Aeon Bioscience Company Overview
    • 5.5.1 Aeon Bioscience Pipeline Products & Ongoing Clinical Trials Overview
  • 5.6 AlviMedica Medical Technologies Inc Company Overview
    • 5.6.1 AlviMedica Medical Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview
  • 5.7 B. Braun Melsungen AG Company Overview
    • 5.7.1 B. Braun Melsungen AG Pipeline Products & Ongoing Clinical Trials Overview
  • 5.8 Biosensors International Group Ltd Company Overview
    • 5.8.1 Biosensors International Group Ltd Pipeline Products & Ongoing Clinical Trials Overview
  • 5.9 Biotronik AG Company Overview
    • 5.9.1 Biotronik AG Pipeline Products & Ongoing Clinical Trials Overview
  • 5.10 Biotronik SE & Co KG Company Overview
    • 5.10.1 Biotronik SE & Co KG Pipeline Products & Ongoing Clinical Trials Overview
  • 5.11 Boston Scientific Corp Company Overview
    • 5.11.1 Boston Scientific Corp Pipeline Products & Ongoing Clinical Trials Overview
  • 5.12 Cardionovum GmbH Company Overview
    • 5.12.1 Cardionovum GmbH Pipeline Products & Ongoing Clinical Trials Overview
  • 5.13 Cardiorev Pte Ltd (Inactive) Company Overview
    • 5.13.1 Cardiorev Pte Ltd (Inactive) Pipeline Products & Ongoing Clinical Trials Overview
  • 5.14 Columbia University Company Overview
    • 5.14.1 Columbia University Pipeline Products & Ongoing Clinical Trials Overview
  • 5.15 Concept Medical Inc Company Overview
    • 5.15.1 Concept Medical Inc Pipeline Products & Ongoing Clinical Trials Overview
  • 5.16 Cordis Corp Company Overview
    • 5.16.1 Cordis Corp Pipeline Products & Ongoing Clinical Trials Overview
  • 5.17 DISA Vascular (Pty) Ltd Company Overview
    • 5.17.1 DISA Vascular (Pty) Ltd Pipeline Products & Ongoing Clinical Trials Overview
  • 5.18 Elixir Medical Corp Company Overview
    • 5.18.1 Elixir Medical Corp Pipeline Products & Ongoing Clinical Trials Overview
  • 5.19 Envision Scientific Pvt Ltd Company Overview
    • 5.19.1 Envision Scientific Pvt Ltd Pipeline Products & Ongoing Clinical Trials Overview
  • 5.20 I.B.S. S.p.A. Company Overview
    • 5.20.1 I.B.S. S.p.A. Pipeline Products & Ongoing Clinical Trials Overview

6 Drug Eluting Stents (DES)- Recent Developments

  • 6.1 Nov 19, 2019: Medtronic reports second quarter financial results for the year 2019
  • 6.2 Nov 14, 2019: Medtronic highlights leadership in inclusion, diversity, and equity in 2019 integrated performance report
  • 6.3 Nov 13, 2019: Abbott announces Robert B. Ford to Succeed Miles D. White as Chief Executive Officer on March 31, 2020
  • 6.4 Oct 30, 2019: Orsiro Coronary Drug-Eluting Stent receives market approval in China
  • 6.5 Oct 23, 2019: Boston Scientific announces results for third quarter 2019

7 Appendix

  • 7.1 Methodology
  • 7.2 About GlobalData
  • 7.3 Contact Us
  • 7.4 Disclaimer

List of Tables

  • Table 1: Drug Eluting Stents (DES) - Pipeline Products by Stage of Development
  • Table 2: Drug Eluting Stents (DES) - Pipeline Products by Territory
  • Table 3: Drug Eluting Stents (DES) - Pipeline Products by Regulatory Path
  • Table 4: Drug Eluting Stents (DES) - Pipeline Products by Estimated Approval Date
  • Table 5: Drug Eluting Stents (DES) - Ongoing Clinical Trials
  • Table 6: Drug Eluting Stents (DES) Companies - Pipeline Products by Stage of Development
  • Table 7: Drug Eluting Stents (DES) - Pipeline Products by Stage of Development
  • Table 8: Aachen Resonance GmbH Pipeline Products & Ongoing Clinical Trials Overview
  • Table 9: ARtax Coronary Stent - Product Status
  • Table 10: ARtax Coronary Stent - Product Description
  • Table 11: Abbott Vascular Inc Pipeline Products & Ongoing Clinical Trials Overview
  • Table 12: Xience SBA Everolimus Eluting Coronary Stent System - Product Status
  • Table 13: Xience SBA Everolimus Eluting Coronary Stent System - Product Description
  • Table 14: XIENCE Thin man DES - Product Status
  • Table 15: XIENCE Thin man DES - Product Description
  • Table 16: ZoMaxx Drug Eluting Coronary Stent System - Product Status
  • Table 17: ZoMaxx Drug Eluting Coronary Stent System - Product Description
  • Table 18: Abbott Vascular Inc - Ongoing Clinical Trials Overview
  • Table 19: Xience SBA Everolimus Eluting Coronary Stent System - A Multi-center, Randomized, Controlled Trial to Demonstrate the Safety and Effectiveness of the MiStent II for the Revascularization of Coronary Arteries: CRYSTAL Study
  • Table 20: Xience SBA Everolimus Eluting Coronary Stent System - A Prospective Global Randomized Trial Assessing the Safety and Efficacy of the BuMA Supreme Biodegradable Drug Coated Coronary Stent System for Coronary Revascularization in Patients with Stable Coronary Artery Disease or Non-ST Segment Elevation Acute Coronary Syndromes
  • Table 21: Xience SBA Everolimus Eluting Coronary Stent System - A Prospective Multicenter Randomized Post Market All-comer Trial to Assess the Safety and Effectiveness of the Supraflex Sirolimus-eluting Coronary Stent System for the Treatment of Atherosclerotic Lesion(s)
  • Table 22: Xience SBA Everolimus Eluting Coronary Stent System - A Prospective, Open Label, Multi-center Trial of Firehawk Coronary Stent System in the Treatment of Coronary Chronic Total Artery Occlusion Lesion(S) by Optical Coherent Tomography (OCT) and Coronary Angiography
  • Table 23: Xience SBA Everolimus Eluting Coronary Stent System - A Safety Evaluation of 3-month Dual Antiplatelet Therapy in Subjects at High Risk of Bleeding Undergoing Percutaneous Coronary Intervention with XIENCE
  • Table 24: Xience SBA Everolimus Eluting Coronary Stent System - Polish Bifurcation Optimal Treatment Strategy Study for Left Main Bifurcation Percutaneous Coronary Intervention (PCI)
  • Table 25: Xience SBA Everolimus Eluting Coronary Stent System - Short and Optimal Duration of Dual Antiplatelet Therapy-2 Study
  • Table 26: XIENCE Thin man DES - A Safety Evaluation of 3-month Dual Antiplatelet Therapy in Subjects at High Risk of Bleeding Undergoing Percutaneous Coronary Intervention with XIENCE
  • Table 27: Adcomp Technologies Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 28: Dual Drug Eluting Stent - Product Status
  • Table 29: Dual Drug Eluting Stent - Product Description
  • Table 30: Advanced Bifurcation Systems Inc Pipeline Products & Ongoing Clinical Trials Overview
  • Table 31: Stenting System - Drug Eluting Stent - Product Status
  • Table 32: Stenting System - Drug Eluting Stent - Product Description
  • Table 33: Aeon Bioscience Pipeline Products & Ongoing Clinical Trials Overview
  • Table 34: Drug Eluting Stent - Product Status
  • Table 35: Drug Eluting Stent - Product Description
  • Table 36: AlviMedica Medical Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview
  • Table 37: Cre8 DES - Product Status
  • Table 38: Cre8 DES - Product Description
  • Table 39: Cre8 EVO DES - Product Status
  • Table 40: Cre8 EVO DES - Product Description
  • Table 41: DES - Coracto - Product Status
  • Table 42: DES - Coracto - Product Description
  • Table 43: AlviMedica Medical Technologies Inc - Ongoing Clinical Trials Overview
  • Table 44: Cre8 DES - A Prospective, Multi-center, Open Label, Randomized Controlled, Two Arm Study Evaluating Safety and Efficacy of the Permanent Polymer Zotarolimus Eluting Stent Resolute Integrity Compared to the Polymer Free Amphilimus Eluting Stent Cre8
  • Table 45: Cre8 DES - A Prospective, Multi-center, Randomized Controlled Trial Evaluating the Safety and Efficacy of the CRE8 Sirolimus-Eluting Stent Versus the RESOLUTE Zotarolimus-eluting Stent in the Treatment of Patients with De Novo Coronary Artery Lesions
  • Table 46: Cre8 DES - A Prospective, Multi-center, Single-arm Observational Registry Trial Evaluating the Safety and Efficacy of CRE8 Sirolimus-Eluting Stent in the Treatment of Patients With De Novo Coronary Artery Lesions
  • Table 47: Cre8 DES - Prove ART (Abluminal Reservoir Technology) Clinical Benefit in Alla Comers Patients
  • Table 48: Cre8 DES - Safety and Performance Assessment of Coronary Drug-eluting Stent CRE8 : Post-market Observational Study
  • Table 49: Cre8 DES - Second-generation Drug-eluting Stents in Diabetes: A Randomized Trial: The SUGAR Trial
  • Table 50: Cre8 EVO DES - Randomized 2x2 Factorial Trial Comparing the Cre8 Amphilimus-sirolimus Eluting Stent versus the Synergy Everolimus-eluting Stent and a Personalized versus Standard Duration of Dual Antiplatelet Therapy in All-comers Patients Undergoing Percutaneous Coronary Intervention
  • Table 51: B. Braun Melsungen AG Pipeline Products & Ongoing Clinical Trials Overview
  • Table 52: Coroflex DEBlue - Product Status
  • Table 53: Coroflex DEBlue - Product Description
  • Table 54: Biosensors International Group Ltd Pipeline Products & Ongoing Clinical Trials Overview
  • Table 55: BioFreedom Drug Coated Stent - Product Status
  • Table 56: BioFreedom Drug Coated Stent - Product Description
  • Table 57: Biosensors International Group Ltd - Ongoing Clinical Trials Overview
  • Table 58: BioFreedom Drug Coated Stent - A Prospective Study of the BioFreedom Biolimus A9 Drug Coated Stent in Patients at High Risk for Bleeding
  • Table 59: BioFreedom Drug Coated Stent - A Randomized Controlled Comparison Between One Versus More Than Six Months of Dual Antiplatelet Therapy After Biolimus A9-eluting Stent Implantation
  • Table 60: BioFreedom Drug Coated Stent - A Study Evaluating the Safety and Efficacy of the BioFreedom Biolimus A9 Coated Cobalt Chromium Coronary Stent System in Patients at High Risk of Bleeding
  • Table 61: BioFreedom Drug Coated Stent - Asian Registry of the BioFreedom BA9 Drug-Coated Coronary Stent for Patients with ST Elevation Myocardial Infarction (STEMI) Undergoing Percutaneous Coronary Intervention (PCI)
  • Table 62: BioFreedom Drug Coated Stent - BioFreedom PK Study in Patients with CAD Who Receive the BioFreedom Biolimus A9 Stent
  • Table 63: BioFreedom Drug Coated Stent - Evaluation of Effectiveness and Safety of BioFreedom Stent in Routine Clinical Practice: A Multicenter, Prospective Observational Study
  • Table 64: BioFreedom Drug Coated Stent - Evaluation of Effectiveness and Safety of the First, Second, and New Drug-eluting Stents in Routine Clinical Practice
  • Table 65: BioFreedom Drug Coated Stent - Prospective Multicenter Observational Study for Evaluating Efficacy and Safety of Biofreedom Stent in Patients with Coronary Artery Disease: Biofreedom Registry
  • Table 66: BioFreedom Drug Coated Stent - Randomized Comparison of a Polymer-free Biolimus-eluting BioFreedom Stent with a Biodegradable-polymer Sirolimus-eluting Orsiro Stent in Patients Treated with Percutaneous Coronary Intervention
  • Table 67: BioFreedom Drug Coated Stent - Randomized Comparison of Vascular Healing of a Polymer-free Biolimus-eluting BIOFREEDOM Stent with a Biodegradable-polymer Sirolimus-eluting ORSIRO Stent in Patients with ST-segment Elevation Myocardial Infarction
  • Table 68: BioFreedom Drug Coated Stent - Six-month Endothelial and Microvascular Function of the Bioactive Sirolimus-eluting

List of Figures

  • Figure 1: Drug Eluting Stents (DES) - Pipeline Products by Stage of Development
  • Figure 2: Drug Eluting Stents (DES) - Pipeline Products by Territory
  • Figure 3: Drug Eluting Stents (DES) - Pipeline Products by Regulatory Path
  • Figure 4: Drug Eluting Stents (DES) - Pipeline Products by Estimated Approval Date
  • Figure 5: Drug Eluting Stents (DES) - Ongoing Clinical Trials
Back to Top